PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.

Abstract Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.
PMID
Related Publications

Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.

Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats.

Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.

Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.

Authors

Mayor MeshTerms
Keywords

Botulinum toxin

Detrusor overactivity

Multiple sclerosis

Myelomeningocele

Neurogenic

Overactive bladder

Parkinson’s disease

Urinary incontinence

Journal Title the urologic clinics of north america
Publication Year Start




PMID- 28716326
OWN - NLM
STAT- MEDLINE
DA  - 20170718
DCOM- 20170803
LR  - 20170803
IS  - 1558-318X (Electronic)
IS  - 0094-0143 (Linking)
VI  - 44
IP  - 3
DP  - 2017 Aug
TI  - Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor
      Overactivity.
PG  - 463-474
LID - S0094-0143(17)30030-7 [pii]
LID - 10.1016/j.ucl.2017.04.012 [doi]
AB  - Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for
      managing patients with neurogenic detrusor overactivity (NDO) who do not respond 
      to or tolerate oral pharmacologic agents. There is level I evidence that
      intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with
      multiple sclerosis and spinal cord injury is associated with a significantly
      greater achievement of goals and improved performance in urodynamic studies than 
      placebo. Pilot studies or small case series support BTX-A for NDO in patients
      with Parkinson's disease and cerebrovascular accident. BTX-A seems to be
      effective in children with myelomeningocele. However, no adult data exists.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kaviani, Aaron
AU  - Kaviani A
AD  - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite
      2100, Houston, TX 77030, USA.
FAU - Khavari, Rose
AU  - Khavari R
AD  - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite
      2100, Houston, TX 77030, USA. Electronic address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Urol Clin North Am
JT  - The Urologic clinics of North America
JID - 0423221
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - AIM
SB  - IM
MH  - Administration, Intravesical
MH  - Botulinum Toxins, Type A/*administration & dosage
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Neuromuscular Agents/*administration & dosage
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy/etiology
OTO - NOTNLM
OT  - Botulinum toxin
OT  - Detrusor overactivity
OT  - Multiple sclerosis
OT  - Myelomeningocele
OT  - Neurogenic
OT  - Overactive bladder
OT  - Parkinson's disease
OT  - Urinary incontinence
EDAT- 2017/07/19 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/19 06:00
AID - S0094-0143(17)30030-7 [pii]
AID - 10.1016/j.ucl.2017.04.012 [doi]
PST - ppublish
SO  - Urol Clin North Am. 2017 Aug;44(3):463-474. doi: 10.1016/j.ucl.2017.04.012.